-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CIrWEu0SBgjaI86hKkd9unh11m47Pfn/j1eVHgC+svT1kYE/f531TIXuWiXhAVV/
 SzTn2/XzLYqXL8f63ZNSuQ==

<SEC-DOCUMENT>0000950123-10-107181.txt : 20101119
<SEC-HEADER>0000950123-10-107181.hdr.sgml : 20101119
<ACCEPTANCE-DATETIME>20101118213418
ACCESSION NUMBER:		0000950123-10-107181
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20101118
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20101119
DATE AS OF CHANGE:		20101118

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MELA SCIENCES, INC. /NY
		CENTRAL INDEX KEY:			0001051514
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				133986004

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-51481
		FILM NUMBER:		101203937

	BUSINESS ADDRESS:	
		STREET 1:		50 SOUTH BUCKHOUT STREET
		STREET 2:		SUITE 1
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533
		BUSINESS PHONE:		914-591-3783

	MAIL ADDRESS:	
		STREET 1:		50 SOUTH BUCKHOUT STREET
		STREET 2:		SUITE 1
		CITY:			IRVINGTON
		STATE:			NY
		ZIP:			10533

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ELECTRO OPTICAL SCIENCES INC /NY
		DATE OF NAME CHANGE:	19971216
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>y87881e8vk.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML>
<HEAD>
<TITLE>e8vk</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 1pt solid black; font-size: 1pt">&nbsp;</DIV>




<DIV align="center" style="font-size: 14pt; margin-top: 12pt"><B>UNITED STATES<BR>
SECURITIES AND EXCHANGE COMMISSION</B>
</DIV>

<DIV align="center" style="font-size: 12pt"><B>Washington, D.C. 20549</B>
</DIV>

<DIV align="center" style="font-size: 18pt; margin-top: 12pt"><B>FORM 8-K</B>
</DIV>


<DIV align="center" style="font-size: 12pt; margin-top: 12pt"><B>CURRENT REPORT<BR>
Pursuant to Section&nbsp;13 or 15(d) of The Securities Exchange Act of 1934</B>
</DIV>

<!-- xbrl,dc -->
<DIV align="center" style="font-size: 10pt; margin-top: 12pt"><B>Date of Report (Date of earliest event reported): November&nbsp;18, 2010</B></DIV>
<!-- /xbrl,dc -->

<DIV align="center" style="font-size: 24pt; margin-top: 12pt"><B>MELA Sciences, Inc.</B>
</DIV>

<DIV align="center" style="font-size: 10pt">(Exact name of registrant as specified in its charter)</DIV>


<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
    <TD width="5%">&nbsp;</TD>
    <TD width="30%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom">
    <TD align="center" valign="top"><B>Delaware</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>000-51481</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>13-3986004</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(State or other jurisdiction
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Commission
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(IRS Employer</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">of incorporation)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">File Number)
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">Identification No.)</TD>
</TR>

</table>
</div>
<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="48%">&nbsp;</TD>
    <TD width="4%">&nbsp;</TD>
    <TD width="48%">&nbsp;</TD>
</TR>
<TR></TR>
<!-- End Table Head -->
<!-- Begin Table Body -->

<TR valign="bottom">
    <TD align="center" valign="top"><B>50 South Buckhout Street, Suite&nbsp;1</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top"><B>10533</B></TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top"><B>Irvington, New York</B>
</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">(Zip Code)</TD>
</TR>
<TR valign="bottom">
    <TD align="center" valign="top">(Address of principal executive offices)</TD>
    <TD>&nbsp;</TD>
    <TD align="center" valign="top">&nbsp;</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">Registrant&#146;s telephone number, including area code <B>(914)&nbsp;591-3783</B></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 12pt">(Former name or former address, if changed since last report.)</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instructions
A.2. below):
</DIV>


<DIV style="margin-top: 6pt">
<TABLE width="100%" border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt">

<TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12)</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))</TD>
</TR>

<TR>
    <TD style="font-size: 6pt">&nbsp;</TD>
</TR><TR valign="top" style="font-size: 10pt; color: #000000; background: transparent">
    <TD width="1%" nowrap align="left"><FONT style="font-family: Wingdings">&#111;</FONT></TD>
    <TD width="1%">&nbsp;</TD>
    <TD>Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))</TD>
</TR>

</TABLE>
</DIV>

<DIV style="width: 100%; border-bottom: 1pt solid black; margin-top: 10pt; font-size: 1pt">&nbsp;</DIV>
<DIV style="width: 100%; border-bottom: 2pt solid black; font-size: 1pt">&nbsp;</DIV>





<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>

<DIV style="font-family: 'Times New Roman',Times,serif">

<!-- TOC -->
<A name="toc"><DIV align="CENTER" style="page-break-before:always"><U><B>TABLE OF CONTENTS</B></U></DIV></A>

<P><CENTER>
<TABLE border="0" width="90%" cellpadding="0" cellspacing="0">
<TR>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="3%"></TD>
	<TD width="76%"></TD>
</TR>
<TR><TD colspan="9"><A HREF="#000">Item&nbsp;8.01 &#151; Other Events</A></TD></TR>
<TR><TD colspan="9"><A HREF="#001">Item&nbsp;9.01 &#151; Financial Statements and Exhibits</A></TD></TR>
<TR><TD colspan="9"><A HREF="#002">SIGNATURES</A></TD></TR>
<TR><TD colspan="9"><A HREF="#003">EXHIBIT INDEX</A></TD></TR>
<TR><TD colspan="9"><A HREF="y87881exv99w1.htm">EX-99.1</A></TD></TR>
</TABLE>
</CENTER>
<!-- /TOC -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>




<!-- link1 "Item&nbsp;8.01 &#151; Other Events" -->
<DIV align="left"><A NAME="000"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;8.01 &#151; Other Events</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">On November&nbsp;18, 2010, MELA Sciences, Inc. (the &#147;Company&#148;) issued a press release announcing the
results of the U.S. Food and Drug Administration&#146;s (&#147;FDA&#148;) General and Plastic Surgery Devices
Panel meeting in connection with the FDA&#146;s review of the Company&#146;s pre-market approval application
for MelaFind<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>. The text of this press release is attached as Exhibit&nbsp;99.1 and is
incorporated herein by reference.
</DIV>

<!-- link1 "Item&nbsp;9.01 &#151; Financial Statements and Exhibits" -->
<DIV align="left"><A NAME="001"></A></DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Item&nbsp;9.01 &#151; Financial Statements and Exhibits</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">(d)&nbsp;Exhibits<I>.</I>
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>Exhibit No.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>Description</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MELA Sciences, Inc. Press Release, dated November&nbsp;18, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "SIGNATURES" -->
<DIV align="left"><A NAME="002"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>SIGNATURES</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused
this report to be signed on its behalf by the undersigned hereunto duly authorized.
</DIV>


<TABLE width="100%" border="0" cellspacing="0" cellpadding="0" style="font-size: 10pt">
<TR>
    <TD width="48%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="1%">&nbsp;</TD>
    <TD width="35%">&nbsp;</TD>
    <TD width="15%">&nbsp;</TD>
</TR>
<TR>
    <TD valign="top" align="left">&nbsp;</TD>
    <TD colspan="3" align="left">MELA Sciences, Inc.<BR>
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">Date: November 18, 2010&nbsp;</TD>
    <TD valign="top">By:&nbsp;&nbsp;</TD>
    <TD colspan="2" style="border-bottom: 1px solid #000000" align="left">/s/ Richard I. Steinhart
&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">Chief Financial Officer&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR><TR>
    <TD align="left">&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD colspan="2" align="left">(Principal Financial Officer)&nbsp;</TD>
    <TD>&nbsp;</TD>
</TR>
<TR>
    <TD colspan="5">&nbsp;</TD>
</TR>
</TABLE>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always"><A HREF="#toc">Table of Contents</A></H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<!-- link1 "EXHIBIT INDEX" -->
<DIV align="left"><A NAME="003"></A></DIV>

<DIV align="center" style="font-size: 10pt; margin-top: 18pt">EXHIBIT INDEX
</DIV>

<DIV align="center">
<TABLE style="font-size: 10pt" cellspacing="0" border="0" cellpadding="0" width="100%">
<!-- Begin Table Head -->
<TR valign="bottom">
    <TD width="7%">&nbsp;</TD>
    <TD width="3%">&nbsp;</TD>
    <TD width="90%">&nbsp;</TD>
</TR>
<TR style="font-size: 8pt" valign="bottom">
    <TD nowrap align="left"><B>EXHIBIT NO.</B></TD>
    <TD>&nbsp;</TD>
    <TD nowrap align="center"><B>DESCRIPTION</B></TD>
</TR>

<!-- End Table Head -->
<!-- Begin Table Body -->
<TR valign="bottom"><!-- Blank Space -->
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">&nbsp;</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">&nbsp;</TD>
</TR>
<TR valign="bottom">
    <TD valign="top"><DIV style="margin-left:0px; text-indent:-0px">99.1
</DIV></TD>
    <TD>&nbsp;</TD>
    <TD align="left" valign="top">MELA Sciences, Inc. Press Release, dated November&nbsp;18, 2010</TD>
</TR>
<!-- End Table Body -->
</TABLE>
</DIV>



<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>y87881exv99w1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML>
<HEAD>
<TITLE>exv99w1</TITLE>
</HEAD>
<BODY bgcolor="#FFFFFF">
<!-- PAGEBREAK -->
<DIV style="font-family: 'Times New Roman',Times,serif">


<DIV align="right" style="font-size: 10pt; margin-top: 12pt"><B>Exhibit&nbsp;99.1</B>
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><IMG src="y87881y8788100.gif" alt="(MELA SCIENCES LOGO)">
</DIV>


<DIV align="center" style="font-size: 10pt; margin-top: 18pt"><B>MELA Sciences Announces FDA Advisory Panel Votes Positively<BR>
for MelaFind</B><SUP style="FONT-size: 85%; vertical-align: text-top"><B><SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> </B></SUP><B>on Safety, Efficacy and Risk/Benefit Ratio</B>
</DIV>


<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B><I>Decision Based on Data from Largest Prospective Study Ever Conducted in Melanoma Detection</I></B>
</DIV>

<DIV align="Center" style="font-size: 10pt; margin-top: 6pt"><B><I>- Company to Host Conference call November&nbsp;19 at 7:30am ET -</I></B>
</DIV>
<DIV align="left" style="font-size: 10pt; margin-top: 6pt"><B>COLLEGE PARK, MD &#151;  (November&nbsp;18, 2010) </B>&#151; MELA Sciences, Inc. (NASDAQ: MELA) today announced that
the General and Plastic Surgery Devices Panel appointed by the U.S. Food and Drug Administration
(FDA)&nbsp;voted by majority that, for its proposed indications, MelaFind<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> is safe and
effective and that its benefits outweigh the risks.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;We are extremely pleased with the results of today&#146;s panel vote and look forward to working with
the FDA during its ongoing review of the MelaFind PMA application,&#148; said Joseph V. Gulfo, MD,
President and CEO of MELA Sciences. &#147;Melanoma is virtually 100% curable if detected at its earliest
stage. The unfortunate reality is that one person in the U.S. dies from the disease every hour and
it&#146;s the number one cancer killer in women ages 30-35. We designed MelaFind<SUP style="FONT-size: 85%; vertical-align: text-top"> </SUP>to provide
clinicians with objective information that can aid their decision on whether or not to biopsy a
pigmented skin lesion that has characteristics of melanoma at its earliest stage.&#148;
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;I believe that MelaFind can be a valuable tool to provide input into the decision to biopsy
suspicious skin lesions and may ultimately help save lives,&#148; said Darrell Rigel, MD, Clinical
Professor of Dermatology at New York University Medical School.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">&#147;I believe that this will also help dermatologists who evaluate pigmented skin lesions under the
microscope to be more accurate in diagnosis,&#148; said Clay J. Cockerell, MD, Clinical Professor of
Dermatology &#038; Pathology, University of Texas southwest Medical Center, Dallas, TX.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The FDA will take into account, among other things, the panel&#146;s recommendation in making its final
approval decision. The FDA has not provided a date as to when it will make a decision regarding
the MelaFind<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> PMA application.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Conference Call and Webcast</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MELA Sciences will host a conference call on Friday, November&nbsp;19 at 7:30 am ET. To participate,
please dial 866-783-2139 fifteen minutes before the conference is scheduled to begin. Callers
outside of the U.S. should dial &#043;857-350-1598. The conference call passcode is &#147;MELA Sciences.&#148; A
live webcast of this call will be available in the investor relations section of
www.melasciences.com. A webcast replay of the call will be
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">available for two weeks on the company&#146;s website or by dialing 888-286-8010. Callers outside of the
US should dial &#043;617-801-6888. The replay participant code is 45603438.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About MELA Sciences</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">MELA Sciences is a medical technology company focused on developing MelaFind<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP>.
MelaFind<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> is a non-invasive and objective multi-spectral computer vision system designed
to aid physicians in the detection of early melanoma from among clinically atypical (those having
one or more clinical or historical characteristics of melanoma, such as asymmetry, border
irregularity, color variegation, diameter greater than 6 millimeters, evolving, patient concern,
regression, and ugly duckling) cutaneous pigmented lesions that are non-ulcerated, not bleeding,
and less than 2.2 centimeters in diameter, when a physician chooses to obtain additional
information before making a final decision to biopsy to rule out melanoma.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">The MelaFind<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> Pre-Market Approval (PMA)&nbsp;application was filed with the U.S. Food and
Drug Administration (FDA)&nbsp;in June&nbsp;2009 and is currently under review at the FDA. MELA Sciences
cannot predict either the timing of the FDA&#146;s decision on the PMA application or the outcome. FDA
approval is required prior to marketing MelaFind<SUP style="FONT-size: 85%; vertical-align: text-top">&#174;</SUP> in the United States.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For more information on MELA Sciences, visit www.melasciences.com.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>About Melanoma</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">Melanoma is the deadliest form of skin cancer, responsible for approximately 75% of skin cancer
fatalities. The melanoma rate has continued to increase with an estimated 120,000 new cases
projected in 2010. A recent National Cancer Institute report published in the July&nbsp;10, 2008 online
edition of the Journal of Investigative Dermatology indicates that annual incidence of melanoma
among young adult Caucasian women rose 50% between 1980 and 2004. Melanoma is the most common
cancer in women age 25 to 29 and the number one cancer killer of women age 30 to 35. Although no
cure is currently available for advanced-stage melanoma, if caught early, melanoma is virtually
100% curable.
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 12pt"><B>Safe Harbor</B>
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">This press release includes &#147;forward-looking statements&#148; within the meaning of the Private
Securities Litigation Reform Act of 1995. These statements include but are not limited to our
plans, objectives, expectations and intentions and other statements that contain words such as
&#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;estimates,&#148; &#147;expects,&#148; &#147;contemplates,&#148; &#147;anticipates,&#148; &#147;plans,&#148; &#147;intends,&#148;
&#147;believes&#148; and variations of such words or similar expressions that predict or indicate future
events or trends, or that do not relate to historical matters. These statements are based on our
current beliefs or expectations and are inherently subject to significant uncertainties and changes
in circumstances, many of which are beyond our control. There can be no assurance that our beliefs
or expectations
</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>

<!-- PAGEBREAK -->
<P><HR noshade><P>
<H5 align="left" style="page-break-before:always">&nbsp;</H5><P>

<DIV style="font-family: 'Times New Roman',Times,serif">
<DIV align="left" style="font-size: 10pt; margin-top: 6pt">will be achieved. Actual results may differ materially from our beliefs or expectations due to
economic, business, competitive, market and regulatory factors. We base our forward-looking
statements on information currently available to us, and we assume no obligation to update them.
</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For further information contact:
</DIV>


<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For Investors:<BR>
David Carey<BR>
Lazar Partners, Ltd.<BR>
646-871-8485

</DIV>

<DIV align="left" style="font-size: 10pt; margin-top: 6pt">For Media:<BR>
Hollister Hovey<BR>
Lazar Partners, Ltd.<BR>
646-871-8485

</DIV>


<P align="center" style="font-size: 10pt"><!-- Folio -->&nbsp;<!-- /Folio -->
</DIV>



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>y87881y8788100.gif
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 y87881y8788100.gif
M1TE&.#EATP!-`/<``-+5X^GJ[2A5G#9>HI:ERH*3O6%[L=?9YSIAHZ&MS"=4
MG'2-NUE\LO#Q\LK-WC);GMG;Y9.AQ=O>Z'>.N["\U_S\_'N1OJJUT?CX]$9I
MIXJ;PR95FZ&PT*>QSOKZ][O"UZVXTUUVK=W@Z<S1XOKY^&6`LT)FI+W$VD%H
MI_;V]O'R]$UNJM_AZ6R#M"Q8G869P5)SJ_S[^R56G4URK/GZ^.+D[<71X??X
M]N;H[IFER?7U\K2YUL7,WO+T]<+$VIJIR>[O\[.^UDELJ/KY]N3F[>#BZ]#2
MX2=6G,;3Y6V)N>KK\/;W\\C.W[?`UKO&VEMXKR)4FRE6G'^0O9ZNSN[N\>CJ
M\%)MJ(ZAQGN2O[C"V&N&N._P\I*>Q<')W)6CR,7)W;W`V7*%M<K0X/?W]2!4
MG("7P)BBQK"XT9*JS_3T]"U7G<W3XCE<GL[5Y7Z/OTAFI+>[T51UKEU_M*^Z
MU)ZHR9JJS%5QJN+CZ214GB)6G+F]U59SK<C2XWZ4OE%TK;/!V/GZ]^CFZ_CX
M\M;9X^;H\,W0W^3EZ_?X]WJ.O)2DQR96GO/T]BU5F_#O\>WO[^SM\"-6G9NL
MR%9XKL?*VL+(VBY;GQY5G'R-N<#&W'B*NO7V]/;W^?/S\RA8GB!6G9>DR'2*
MN-C<Z'B/NR%4GB)6GOKZ^?O[^B15G?[^_OKZ^/O[^?S\^R55G255G/S\^B-5
MGOKZ^OGY^/O[^W>0O"-4G?OZ^?OZ^OGY]R)5G?K[^B15G/O\^_CX]_GY]B-4
MG/GY^?CX]B-5G"14G2)5G")4G"14G/OZ^/CY^/CY]_GX^/O[^/K[^?CY]OGX
M]_GX]B)4G?CX^"54G/K[^/GZ]?CY^254G?GY]"%6GOGY^DMFJ'*'N/O\_/7V
M]NWN\O3S]N#CYXJ7P/#P\)*GR)FLSYBGR9NLR[.XT51PJ/W]_"!3F[['V?S[
M_,#"V#U@H2I4FF2&N"94FGV1O-'2W)2DR5-RK.3CZ/OZ^]#9Y5=UK-/8Y;.U
MS</,V7J*ML'.W"15GOW]_2'Y!```````+`````#3`$T```C_`/^54G6#A(=-
M(G@$F1-DGQ)>AWZ5,E;AG\6+&#-JU.B!!HU'1H*`H*`.PJ)8)&+%*K4QHRU5
MI22F+%4J5JJ;.'/JW(FSE[%4RRRNXGFSUZU4%5LJ7<IT([*4))BEJ8&CQR%F
MMYR1,&0`02<4&E8$$]'@R8`#-%JBL^6A5Q4.)5!$R0,IV)$9&AYY4*9J5=._
M%GLUX.#G@0PRN(X@8,#%D"U@J9I**S6SU+%'`'SLV,RYL^?/G,V!:6#+HA+0
MF\VE*;4+L.O7_XYA2`6A@"040B19:#+&&:PQ1(*\*:($Q0IR8D(\6)-VXRI5
MX2(,&-;JR)$-4:*P"@:IG1%K)&3!_UZ*`Y\O7:T47(^R08"N3E(>169::DB`
M)I=6/#BEB)6,_P`&*."``.:1P1VP6(0$@?\QHH0UVXPGH5+.]!#!`Y`,<]U_
M4*S`1"JFT&!#-L`X,X`>0H@S3C9=>-!2!1@@(HP_--9H(XT(M(&!>!->Y,$-
MWPCA#QYXW&CC!GND84LO064$BS."0%!"%*T8:>656"J`0@U^_8,$EE$`H4I2
M/4YHBRP5I%"`+ZQ<&84(R)0R(BPD/*`)&_0X8$46+FZ$S@F^G()EC0IDH$*7
M9:J"C#:"$GGE*5$($$$OOR2842DX@./",*\H,.BG66[9Y9=NBDEFF>-18THO
M0732BB]7%O]C0#.Q])--*N$,0`(#?CQB``6\J&5%'FU^VLHI7"#:8RHG0$$+
M'C)@B0N5)HB@DD9B($#&!M8I`NJW-VK)I8)@FHKJA+%XH`0"Q.01S960G`*"
M-56P<TPC>APBP0&I3"*",2T1XH)VH+;RBA!$F#)FCS0\(<"S@]*B"RL"!#%$
M+!>9`LP:*+SB,2W^@`SNR.*.6N["YXY'`@8=O,)*H%<^(X`D5)1R4PRRY.)*
M7\;TU1(8`D0AZ*>TR!!%$"3TLDZ/-41QQ-"@GO(#31?%H@(^[XZLM8TEDULJ
MRBF_ELH80G[JRP8N!.'!F;"-H\@&N(`*B0#/+'`+#:?"]HDNI[S_`NXK?=A\
M$087M%+LUEMW[>7)>8?=U!"8'`%J,!L0@P\RM>0"&QJG]/TM*Z\\H`0)C3=5
M"BR+,`"ZR*"^(HHI+%DD@0DPVX@+,4>P0HP,E&_@^^_`!R^\[]$<:(K75H8)
MMN-_Z;""`*V?PDH41O1R_&MH("X`#TB-!XL'A0RPM>NNQ/Y/$VK0XK>-M`2#
M"RYL@#++_/37;__]]8NB@1*'(&^D\J5C7DL&T9Z1O>(%5,,>XEBA#4T$<"FF
M2`4BJC$^493O(F4XQ=-N!#HVT*$!'HB%*49(PA*:\(0DI`D)5.&_&P%0@(`!
M!2LV8,!JE4:!5CJ%#&@!M1K)``'Y>*!2_TJA`@3$S4;28\7A;D2^4JRB`C&8
M@0P,=B,!'`$$MT!3#+;(Q2YZ\8M=#!$LYD.JY)D+AB^*`2RJ4(DHZ,)(2E3B
MC4ZQ@4@D8W-7HD7NUG>D88`@0K`QA0.*P4<:R>`(N*B2E9KXQ%6X0`:LZ*$_
MA&&`15@*C67\WQG1J)%5U,(#=)!6,/YS(SU:80QXM!(N,H`A([WQ"3QZ32P6
M`#HF;D`1>[A2$V51B@8<2P:25$0'>A%+&&;2A9OD)$8JD(I'Q`%+&=@#&21Y
M"EWX@@FI--(K]B"**!B)%@)P`0Z480HA6J0"%2%"!B!Y(UR<0@BST*4%3U>*
M1TB/%JRCT0:R4/^*ZV&2<<K4B"QBD047&"D8VR%'!W('1QEH(0W8Z%-3LF>E
M8.PA"^XPDO1T<8')%/-%%3!%$ZZS1'_X(AUT$(4\RY<+4U`!2ZQP@BD^RKQC
MVNB%`5UF+$H0#",)(!T/(`(.A!`M*ZF!$LR8ST1U"8,[9$"CP"P!"9:A+)!6
MH`^G$(`DSS8(E2YRGBU]Z95B.E-EVK1&.,VI16)0"#44DD91>$48>A&+'XSB
M464PQBT`0U$XSJ`7M#S%C&BD".D]P!$K;$HM9-&`1PK@K:=8P1CB^566NA2F
M,J6IX\X*UV1RL@*KV`4U0%$=(Q5##1*X02^4X`(E2A(7+E`"-/@ZUAG_U.(+
MI\@##6_4"CK4PI]#!,0'L/2*<GC`J]H$ZV7'FEFS`C2GS*Q%/MI!!D_QU@"E
MH,'*7D",2,X1%W3H!6T7.0,2I&$`GMBMC5IA!628\Q^'T(0VL/2`0@B"LLFU
MK%BM1%;-AHVS_DBK,BN@W7*\8ACJK=$1*#`$9ICB%@ZH!"[>^@I("`$8X_WF
M#&S!BP)$`WHWLDLH8M`47@#@`3D\10L6D0KD,E&Y^X6C$U113G3:^,8XSK&.
M5_'$%M[4LVA<Q2\:T(Y6/+9&M%"B";9`@]/!@A,E8*B-7G&$5F#"%6AB2E^9
M"(/R\:"-II4!.6ZXE"%PX(TWFN(&/I`N"ZRT_Q1AQ6PJG`R+.MOYSGC.,YY3
M88OK`5C`G^W%"4KJ#URXYPK62$%25`&"B7$0DN?H!0G(W)(M3[G+I=B"`=!L
M(T70P@[-6<HA0N"M&TV,#4KH!3!</&488TD`'1C$`69-ZUK;^M:X'H0(FN'G
MYP:T`HTP`"2,I(@\+&<(O^A2#!J`@&%P\`ADR`,`0*1EII8/&&9XJS]T<81.
MU*`I-5`#IVOTLB2D@@2WP.^+]8LE7SQ@`/".M[SG3>]ZP]L`W5"&C]$*9!A6
M0!U.,](&/-$";L0BV1:1!0;*4%(].FT!'I!HI:U=$Q9TXIN%O4((@?N/5933
M%#\P]/]>$038E4+=K?]F-^)63B,!S``(-_QSO\,6`]BE0@MV\:DO/E!54\""
M!2C8@/2,)#KS37R1F.Z%,^BA35\HP@`]Z&=&*D""!]LA&/"`XX%X>?(WQYGE
M*W<YS/?=V>4)$':](,(&2)%@&N$B!(>HJBI2P8P^X*(3(+;1-3Y!@FHCO7RJ
M:$8=X*@(/`P@'XN=NBD.48].'*$81L+%!&ZQ#)J@O$9-_#K8MR;VF/L:AK`P
M!C/,T`I=')%K%X#&1VN!C%L`0`V*&/:-CA`'(/A=FYB>R!V.`,E\^H,5Y6B&
MYI:I"A)<`4NC\,$23'YY&F5^N9O76N?)'N"9IRP&O>`$`H@MJ`P8@A=5O4C_
M#)X`C[PK^`A-*`4@.'X12V,>T\>HQ2U"((-QTX@5>\``B9?9"Q4P`$OMP`E5
M9WE>!WW1!R[3MSA?\UX]$D%G<'KDYG0O,`:E$$"JD`6LX'O^<`374`(><`N4
MAA'NYWR89@NPD`L=8&AO50P;,`(<MPHDP`0H=B6@X`$#V'65!6<&>("@DH`R
M9W;,`PLZ4`**Q#Z*(`"#<`O`$'[G1&2$M@%&4P@V<72X5SXV!@`(($F_)P,O
M\%&K<`M2T':3)`"5P`.R@#,$F(.:ITU)%$=N^(9P&(=*U`HST`BQ\X,,."&E
M0`FM="/$$`5[L$4^XQRW<`504"1%Y0])%`^Q8`U4_\AE%V01W)`)P,1!P8`/
MMH<1NW`G15@CNB`#4/=$7-=\_O!\,=9.[?`&&;"*K-B*KOB*L)@!)=`-9/1Y
M`J0,!O`*8B@`K1`$3;$*U#`(`U`D5C(`$-!W&S&"I8AI%Y$*#O`,)>4+D/``
MV(01KL`.Q-")A'4-9M!(HUB`IV@C:G`"&-`+JG".Z)B.ZKB.ZV@,8S`$/(*'
MRE0#CD<,1G($;-``II,*O``.A4>,-B(,/R!Q(DAQ%Y$,G/``;R4,17,%-O-;
MJD`#4J!;/J4(+&!CWZB&.W@D3M!///:1(!F2(CF2J[`-%1"/MGA]5:<!N$!H
M_A`,9N`,-#&3-#F3J4`#M_\@`8QP!!K("B;`"8]X:9$H$$.003?B*&_0`[Q0
M"_5!!"B@"][$0?00"TFQ"FF87SH8CN367)PDCP($$TZ%)4<P!7-``69YEFB9
MEG-@`C(`@33R>!\0E.\WE$>1!9)C)'B@`*%``MDU!%F`=UHH##G0/1UWE>N6
ME9A55EV9DN=B"B0P!^:79JT`!9U3F99YF70T0Y'I#PK@"RT@ER0XE+!@"D2P
M`M!82'B`"Q%``A*1"O$0!=7`1]&"!XI0!!Y0E8:9<HC)7(KY3PL(0Z4P:FYI
M(\7`;0)PG,B9G,IY2S+@;#<B#,40!350"SW6?@:Y5A4`"WWP"M$@2:]@!8"@
M?CC_P`97@@=[<`B$:94XB)5KR$%<Z9MF!(3GH@H$Y)(\>"678`VWT!K6^7?F
MHPJU4`$.P"TE%0Q1``!C1`Z;220RT`',0`)=HIZD:(J)Z5\IXY7,DP+:P$[W
M^2T"4`2EL'\6H8ROP(P680HQ4`'<@``<6B.!H@&Q,`9R4&I(I`@#T`;DA)OK
M>9BP0`-4`#(]Z0159U8@HVT"X`@!ZCBR(`NJ``#M@!X=^BV00`>\`%PD:J(8
M$0,>5E)*Q`:<```#H(4"@`N@L`D9(:%O!COAD($9F&99T%)F)0,`>5/RD8=_
M$0,VHP%PLYE1*G`F,`;*<J5#>1%-V@XEE0=!TP7DH`"$_S:F//""N8EY\^1Q
MIM`),B`,<ZJ(61`>9A4H&EB;A)DRM:`,5?``26:??:I@KS`'IR*H1F<1RY`"
M)>"6+2D#!4!J=VDCNJ`&#9`W:)J#IN!Q)H`+GE9*.0`(N:!CRKJL.F81;>`"
M+F,D4"`&J8`FH,6LV(I.0_&81J,`ZR-82A2M8'<*M-"2/O4*6@!^Z/0/KJH1
M,4`-"3!81E()[O`*F\D*6!"J0A&ISC=/%[$`N+`!;Q4-#Z`.2T`"TD`#Y^@!
M*-2P)V0+R1!!%N&4PP!Y-P(%+1``0U`+)-!2#ONQ"C-"J7`,5M!PUE$)H&`!
M*KNR+-NR+KNR\8``8A@%PS``:_]@#!7(KM>)$=*0"H:@!KH$"3*PF5'P`:7@
MA?Q:BOYJ$1T`2126!R8`!YJ@#!XP=W-6DUB;M301"\S0"_NW"24`!=KH#\4@
M`&&``[TP#7RIM6P[D[%``Z9@"X6@"&]E:+I0`IQ`5R#[L;&P!#\PLZ_P#!J@
ML'[1KAGA"JFP"0P@6+Y',5%)(SST"C.@!+_`GQ?QJUAY$6L0I@L9!;A`!@@@
M"9D`#E[@!03P":>;NJB[NJJKNCG@!6=0I4+Q`@&K36VI!GZ0"1'`NKS;NKR;
M`Y^@#\!``V-`6LZ)>54&!Z709[O0O,[[O-`;O;#`"P'@`F]T./8J``]@"+%0
MN#NK$1W_P`JF!RK%<`K#,`M\Z:M)VT07L0AAX`FHVJ&G(`>E4`L6X0IKP`A0
MD*JER"T)<#&SLP'/,$=DT`XJ<"X54`K6<`FZ(`#6A42)0)4ZZY]*@0/N``D4
M]"DR\&&34`JW>:;KN[3_,`82H`;Q>Y_S6[_G-`8O8+%]J@"08``-$`N\8`$:
M,L!(]`I<$((2DL#34+T;0&BX,`,!4!&&NQ&QH`U\`RJZL`$F`")FA[F'>1%'
MD0/:\0KRFJHI;+\=IR\K4+Y:N'E6Y``TT`LX\`"1<D1`*@!"4`-*U2,)#`NU
MP`^X<X]7M`NK<,0:00(.X`D/_&JZ4`!*(<6Z636I$``&,`S$_\*_-++%^XH!
M<.!6-,J#K;`".$D"':!1D_0*!:"PS-,%4'F/,E`"OT`#>NP2L;`')ZR(&<`"
M@QS"0PD-GZ1IG9#!_.O(_Q!2GW0&E9"(/#@,)U`06R`);_4LM.`"QSA\8;,(
M5F`)`J<AH?`+IXP1AT`"7Z!MQ)8#S/#*.UK(%@$+$G$9=?"X6DR_7"P+?'D+
M'C`"(1"E<9`&P!`+ZJ`&DE0TM"`)*>`!;WPNL%`.N5HC624`+V`,G(.9?0,#
M*Z$4,>`!:L(>.N0?PS!%_K$!(<`)J-02"@,+B&#0?3,+":T1(>4`)8#&KU!Z
MOM`*0L?1*HV9Q"`'O(`Q4Q<#:?`)<?^@!L5Y!(&R`<>RTI89L"X@#R20#,`P
M`1-SF7^H"R>`1J7``B:@B`:-``V`!JTPU50]U<1@!WRI%#-%`TI0`%#PB<70
M)M/3"L'P!$5``LBX$;QD#*)0U57M"Q.0U5.'3K'0`&M0!R&@!L'@"[A`'6[]
MUX#MUK[``)*F$;8`1;'0#9AP!590"9]X.X$-V,00#`8`&;]@""[@#NCAUL&`
M``<,0[&`#!80V;C0`2-``*B=VJ@]#QW@`:^*$1GM`<D``(A@`@I@"6^#``9`
M"=X00J]]$2$E:*JMVO/0!*ZM$<'Z#W-G"[=``@T0"CQ``3\PW-1=W=2=`R!@
M/1H!H*O0"[__%0NWL`42P`1!D`#67=UF8`82X'&PD`^E2]U>8`:4\-OG,A`0
M<-Z)T`&HX#@>5PJ!4`]IP'YJ->`$7N`3LM\TEYTC=(X&WN`._N!+@>`I$U*>
M5"D"#N$8GN$!)>$(G,OH)`M,J.$B_AK*(`L^9PK+X%^KD.(L1.`</N(P/N*F
MH,\TUIL9@:=Q6^`O'N,\#N&IL`@`P`,L0`(`H]9CD`I</.`[WN-,KE:]P`QC
MT`7M``\:5`@B>DX>/`<KX``$N>%-_N4$/JIB\``(<`%?``X!<.6Y#`B_$`_%
M0`=#H.-@/N<!Y9A7@`OF``S6X`S-\*H)G`RA<`&I)N=T7N@"9`NI_T#4$F`-
MV>4*<0N@5)`/:_`()!`.1=`(T.!$*7``(X`#*[0*WD`$*5`#(R`!T(`SE$H(
M:Y`/BV`SFSX"57".$:0"`,`'5;#DAI[K$J(,TO`"4'`&8^`!?N%SS7`/DE`)
MG9``J0`")@`&O,`+).`%:(P/H?!;64`/>H`"`H``3:`*O\!AF"`$+E!?P)`&
M9C``[@`#1<#HC>`&:&P%N*[K\@X8ZB>#)G`"OP!:Z)P/)O`&+W`%1H`!4[`!
M.X#6'2``9D`'`U`"%-@$PZ`&&A`!+M`.#5`3)_``,!`!+R`?"P4."?``YY`"
MIO`"E:`!%\`%\3[O*J\4.0,-<^`""%`.B_\P:44)#SP`#$81"U/`"CL`"#TP
M`"MP`V-0!FK@Z38P#`;0"V,0`JP@`<V-#]N;"[OP"QB0`2$`SPMP!!)``W(@
M!%4P!,V0\BL_]DA\`B80!0N@"220`FQ@!4N0"C&@"K'``3*P`ZEP``*@`4-P
M"R#0"FW`"S:`"UP`"['@!L_`+S4@`&6@S#50#.60%1=@">I0"UKP`.SP[&)/
M]IIO$30`#-FB"!^B!.X`<20`"W)/]W8O!I8@!%J@!7X@`#80"X'O!3'A!KB`
M%FUP"AP@40<@`RN0!*Y?#&=@#!_@#B8P![R0^9NO\C8V&03U`"5@#$4@`U=P
M#"AQ^G6?"DT@`RW_,`]>`+PLD`I\,`KS\`O)8/O\8@-1,`?FLP;!H`6GFP,$
M,`BR0`.8\`:*8`;*O_SR#A`5*IA:5:J"DA4P:E41$`8##1*J8G&0L2/5"%Q>
M2IF*4>'?/SZO",`JY>;5@51M-I13]O$?A&`)5)DJY=*6AQKG&*%RV=/G3Z!!
MA0XE6M3H4:1)DZY:)4N@J1H9GI!(T>Z-"FNU)%*T*`%7"U@Q3'D$*9*D290U
M!(":YA('O#Z'8)ER2:.4AP2=>"KEV]?O7\"!@WI(%8I(J2H3('7@U>L%K00J
M>*69>,JB)B$N`)2RM<B5K)`$?I%`FRI6"#4\L$&KD,*`BTG(L&V)L0O'L!A>
M&J#L%=S;]V_@2FD`*Y%!SHHH!AK$(B%B12<&)8*,X7!D1RD,(QX@2)($D3->
M-EIYH19+"J0#I6J=8#.@A)PBO+JPX9[$`*\&)=YI>2`$U7\``Q1P0`(+-/!`
M!!-4<$$&&UPP%4'^P((!+9IHP)149+$%!PWD>(<)4WBP8(088KDE%$3DT.*"
I6&@0P0U,-`3!@AI,D669?"R08X%`D*DE'W`\[&`,;R[00HXZ5`@(`#L_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
